Literature DB >> 28241919

In Reply.

Barbara Nußbaumer, Gerald Gartlehner.   

Abstract

Year:  2017        PMID： 28241919      PMCID： PMC5331480          DOI： 10.3238/arztebl.2017.0071

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

2.  Ezetimibe-Statin Combination Therapy.

Authors:  Barbara Nußbaumer; Anna Glechner; Angela Kaminski-Hartenthaler; Peter Mahlknecht; Gerald Gartlehner
Journal:  Dtsch Arztebl Int       Date:  2016-07-01       Impact factor: 5.594

3.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

Authors:  Christopher P Cannon; Robert P Giugliano; Michael A Blazing; Robert A Harrington; John L Peterson; Christine McCrary Sisk; John Strony; Thomas A Musliner; Carolyn H McCabe; Enrico Veltri; Eugene Braunwald; Robert M Califf
Journal:  Am Heart J       Date:  2008-09-02       Impact factor: 4.749

4.  How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey.

Authors:  Deborah A Marshall; F Reed Johnson; Nathalie A Kulin; Semra Ozdemir; Judith M E Walsh; John K Marshall; Stephanie Van Bebber; Kathryn A Phillips
Journal:  Health Econ       Date:  2009-12       Impact factor: 3.046
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.